Recruiting

Atopic Dermatitis

Sponsor:

CorEvitas

Code:

NCT04504955

Conditions

Atopic Dermatitis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Observational Non-Interventional Registry

Study Details

Brief summary:

This prospective, non-interventional research registry is designed to study the comparative effectiveness and comparative safety of approved treatments for patients with atopic dermatitis under the care of a licensed dermatologist or qualified physician extender. Secondary objectives include analyzing the epidemiology and natural history of the disease, its comorbidities, and current treatment practices.

Condition or disease :

Atopic Dermatitis

Conditions

Atopic Dermatitis

Study ID

NCT04504955

Start date

Jul 14, 2020

Status verified date

Aug, 2026

Completion date

Dec, 2100

Anticipated

Primary completion date

Dec, 2100

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria Has been diagnosed with AD by a dermatologist or qualified dermatology provider.

2\) Is at least 18 years of age or older and has attained the legal age for consent to procedures involved in the research, under the applicable law of the jurisdiction in which the research is being conducted.

3\) Willing and able to provide consent for participation in the registry. 4) Willing and able to provide Personal Information (full legal name, sex, date of birth, home address zip/postal code, and email address OR phone number at a minimum) if required based on registry location and applicable laws and regulations. 5) Has been prescribed a new Enrollment Eligible Medication. A new therapy is a medication that the subject has never taken before.

1. At the time of registry enrollment OR
2. Within 12 months prior to registry enrollment

Exclusion Criteria:

1)Is participating or planning to participate in a blinded clinical trial for an AD drug.

Follow-Up Criteria

Registry Follow-Up data collection should be done at the time of routine clinical encounters approximately every 6 months. Routine or standard of care clinical encounters may occur in between two registry visits, but the data collected in the Follow-Up forms should cover the time period since the last registry visit.

For planning purposes, each Follow-Up visit is anchored to the date of the last eligible registry visit. A Follow-Up visit is eligible for payment if 150 days have passed since the last visit submission. A Follow-Up visit is not eligible for payment if conducted less than 150 days since the last registry visits except when the EARLY Follow-Up visit Criteria are satisfied.

EARLY Follow-Up Criteria

A registry Follow-Up visit should be conducted whenever a patient is prescribed or receiving the first dose of a new Eligible Medication even if less than 150 days have passed since the last registry visit. When the EARLY Follow-Up criteria are met, the next anticipated registry visit is calculated from the date of the Early Follow-Up visit.

Study Design

Enrollment

10000 participants

Anticipated

Interventions and Outcome Measures

Arms

Atopic Dermatitis

Pts presenting to enrolling sites across in North America and select European countries are invited to enroll if eligible

Interventions

Observational Non-Interventional Registry

Observational Non-Interventional Registry

Primary outcome measure

  • AD epidemiology, presentation, natural history, management, and outcomes [ Time Frame: Through Study completion, an average of 10years ]

Central Contacts and Locations

Central contacts

Locations

CorEvitas, LLC

Recruiting

Waltham, Massachusetts, United States, 02451

Contacts

More Information

Sponsor

CorEvitas

Last update posted

Aug 26, 2026

Last verified

Aug, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by CorEvitas on 2026-08-26.